Scholl et al. (2015) [19] investigated the effects of oral QLT091001 in 18 patients with retinitis pigmentosa (RP) resulting from mutations in the RPE65 or LRAT genes, aged 5 to 65 years. The gene discussed is RPE65; the disease is retinitis pigmentosa 1.